CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 43 enrolled
Drug / intervention
OPS-2071 tabletdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02473393
NCT02473393Phase 2Completed
CompareCT.gov

A Clinical Trial to Assess Three Different Doses of OPS-2071 in Patients With Bacterial Enteritis

Otsuka Pharmaceutical Co., Ltd.·interventional·Posted Jun 16, 2015·Updated Mar 24, 2021

In Brief

A Phase 2 clinical trial evaluating OPS-2071 tablet for Bacterial Enteritis. Completed, enrolled 43 participants across 3 sites in 3 countries.

Detailed Summary

To assess safety, efficacy and pharmacokinetics of multiple dosesin patients with Bacterial Enteritis caused by Clostridium difficile infection(CDI) or Enteric infection.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBacterial Enteritis
CountriesJapan, Singapore, South Korea
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJun 16, 2015
Enrollment StartAug 20, 2015
Primary CompletionMar 14, 2017
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 11.0 years ago

Interventions

OPS-2071 tabletdrug